Evaluation of Serum IL-7 as a Biomarker in Breast Cancer

NCT07133685 | Not Yet Recruiting DMC

• 1 other identifier: Serum IL-7 Breast Cancer
• Study Type: observational
• Target: 140
• Locations: 0 countries
• Sites: N/A

Brief Summary

Breast cancer is one of the most commonly diagnosed cancers and leading cause of cancer-related mortality in women worldwide, posing a serious threat to their health (1). It is a heterogeneous disease, characterized by varying molecular subtypes such as hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2-positive), and triple-negative breast cancer (TNBC) (2). Breast cancer develops as a result of several internal and external factors (3-5). Poor lifestyle choices, environmental factors, and social-psychological factors are all linked to its occurrence. It has been demonstrated that 5% to 10% of breast cancers can be attributed to genetic mutations and family history, while 20% to 30% of breast cancers can be attributed to factors that may be modifiable (6). An early and accurate diagnosis is essential for effective treatment and improved patient survival. The human immune system plays a fundamental role in the defense against malignant diseases by recognizing and eliminating cancerous cells at the early stages of tumor development. Many research has been conducted on various cytokines to assess their role in the development of various tumors. IL-7 is an essential cytokine for the adaptive immune system, which is crucial for the development of B cells, the proliferation and survival of memory T cells and naive T cells, as well as the development of thymic T cells (7). IL-7 action is realized through two main signaling pathways: (Jak-Stat and PI3K-Akt) (8). Through these pathways, it has an impact on the development, survival, proliferation, differentiation and maturity of immune cells such as T-lymphocytes, B-lymphocytes, and natural killer cells (9). IL-7 has strong immunomodulatory act on tumor cells and exerts anti-tumor effects by enhancing tumor eradication or adoptive immunity (10). However, IL-7 may also facilitate tumor progression by activating the same downstream AKT pathways .

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• concentration of the serum level of IL-7 in patients with breast cancer

  concentration of the serum level of IL-7 in patients with breast cancer

  baseline

Study Arms (1)

study group

Female patients diagnosed with Breast cancer based on pathological and radiological confirmation.

Eligibility Criteria

• Age: 18 Years+
• Gender Eligibility Details: female patients
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Female patients diagnosed with Breast cancer based on pathological and radiological confirmation.

You may qualify if:

• Female patients diagnosed with Breast cancer based on pathological and radiological confirmation.
• Age \> 18

You may not qualify if:

• Male
• Patients diagnosed with other malignant diseases

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: residant doctor at Assiut university hospital

Study Record Dates

• First Submitted: August 14, 2025
• First Posted: August 21, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: August 21, 2025

Record last verified: 2025-08